AC Immune's ACI-7104.056 Significantly Slows Parkinson's Disease Progression
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 11 2025
0mins
Source: Globenewswire
- Clinical Trial Success: AC Immune's Phase 2 VacSYn trial of ACI-7104.056 demonstrates, for the first time, that targeting alpha-synuclein pathology with active immunotherapy may slow the progression of Parkinson's disease, marking a significant breakthrough in treatment.
- Strong Safety Profile: The therapy was administered to 34 patients, all treated for at least 12 months, with no clinically relevant adverse events reported, indicating a favorable safety and tolerability profile.
- Robust Immune Response: By week 76, the ACI-7104.056 group exhibited antibody titers over 500 times higher than the placebo group, achieving a 100% responder rate, showcasing the therapy's potential to induce a strong immune response and laying the groundwork for future treatments.
- Stabilization of Biomarkers: The treatment group showed stable levels of neurofilament light chain (NfL), a marker of neuronal damage, while levels increased in the placebo group, suggesting that the therapy may effectively slow neuronal damage, which has significant clinical implications.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ACIU?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ACIU
Wall Street analysts forecast ACIU stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ACIU is 12.00 USD with a low forecast of 12.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 3.400
Low
12.00
Averages
12.00
High
12.00
Current: 3.400
Low
12.00
Averages
12.00
High
12.00
About ACIU
AC Immune SA is a Switzerland-based clinical-stage biopharmaceutical company. The Company focuses on precision medicine for neurodegenerative diseases. It designs, discovers and develops therapeutic, as well as diagnostic products for prevention, diagnosis and treatment of diseases caused by misfolding proteins. Its SupraAntigen and Morphomer technology platforms to create antibodies, small molecules and vaccines designed to address a broad range of neurodegenerative indications, such as Alzheimer's disease (AD). The Company's pipeline includes nine therapeutic product candidates with five in clinical trials, and three diagnostic candidates. Its lead product candidate is Crenezumab, a humanized and monoclonal anti-Abeta antibody for Alzheimer’s disease. It has collaborations with pharmaceutical companies, including Roche/Genentech, Eli Lilly, Biogen, Janssen Pharmaceuticals, Nestle Institute of Health Sciences, Life Molecular Imaging (formerly Piramal Imaging) and Essex Bio-Technology.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
AC Immune Study Indicates Promising Early Results for Immunotherapy in Slowing Parkinson's Disease
Interim Results from VacSYn Trial: AC Immune SA reported promising interim safety and efficacy results from its Phase 2 VacSYn trial for the anti-alpha-synuclein immunotherapy ACI-7104.056, indicating potential slowing of Parkinson's disease progression through stabilization of disease-related biomarkers.
Robust Antibody Response: The treatment induced a strong antibody response against the target antigen, with a 100% responder rate and significantly higher antibody levels in both serum and cerebrospinal fluid compared to the placebo group.
Clinical Measures of Stabilization: Clinical assessments showed that the ACI-7104.056 group did not experience meaningful progression in motor symptoms, contrasting with the expected increase in the placebo group, suggesting a trend toward disease stabilization.
Future Expectations: The trial results are generally safe and well-tolerated, with final data from Part 1 of the VacSYn trial anticipated in mid-2026, while AC Immune's stock saw a notable increase following the announcement.
Continue Reading
AC Immune's ACI-7104.056 Significantly Slows Parkinson's Disease Progression
- Clinical Trial Success: AC Immune's Phase 2 VacSYn trial of ACI-7104.056 demonstrates, for the first time, that targeting alpha-synuclein pathology with active immunotherapy may slow the progression of Parkinson's disease, marking a significant breakthrough in treatment.
- Strong Safety Profile: The therapy was administered to 34 patients, all treated for at least 12 months, with no clinically relevant adverse events reported, indicating a favorable safety and tolerability profile.
- Robust Immune Response: By week 76, the ACI-7104.056 group exhibited antibody titers over 500 times higher than the placebo group, achieving a 100% responder rate, showcasing the therapy's potential to induce a strong immune response and laying the groundwork for future treatments.
- Stabilization of Biomarkers: The treatment group showed stable levels of neurofilament light chain (NfL), a marker of neuronal damage, while levels increased in the placebo group, suggesting that the therapy may effectively slow neuronal damage, which has significant clinical implications.
Continue Reading